Medtronic (NYSE:MDT) announced today that it posted positive 12-month results validating the superiority of its DTM spinal cord stimulation (SCS). Fridley, Minn.-based Medtronic’s multicenter, randomized controlled trial produced statistically significant 12-month data that validated the DTM SCS’ (using the Medtronic Intellis platform) superiority in providing relief for back pain when compared to conventional SCS therapy, according […]
Pain Management
The top 10 medical disruptors of 2021
For the past 18 years, the Cleveland Clinic has predicted what the top 10 medical disruptors will be for the following year. The list of technologies, cultivated by a panel of physicians and scientists at the clinic, was led by Dr. Will Morris, executive medical director of Cleveland Clinic Innovations, and Dr. Akhil Saklecha, managing […]
Abbott enrolls first patient in spinal cord stimulation study
Abbott (NYSE:ABT) announced that it enrolled the first patient in its Distinct study to investigate its BurstDR spinal cord stimulation (SCS). The Distinct (dorsal spinal cord stimulation vs. medical management for treatment of low back pain) study seeks to investigate the efficacy of BurstDR SCS compared with conventional medical management (CMM) in people with chronic low […]
Boston Scientific launches spinal cord stimulator systems in Europe
Boston Scientific (NYSE:BSX) announced that it launched its WaveWriter Alpha spinal cord stimulator (SCS) system portfolio in Europe. Marlborough, Mass.-based Boston Scientific’s portfolio includes four MRI-conditional, Bluetooth-enabled implantable pulse generators (IPGs) and offers expanded personalization, rechargeable and non-rechargeable options and access to waveforms covering multiple areas of pain, according to a news release. SCS therapies relieve […]
NeuroMetrix launches Quell app for Apple Watch
NeuroMetrix (NSDQ:NURO) announced that it launched the Quell Watch App for transcutaneous electrical nerve stimulation (TENS). Woburn, Mass.-based NeuroMetrix’s Quell app, which is now available for download from the Apple App Store, allows users of the Quell system to personalize and manage their therapy discreetly on iPhone and Android smartphones, according to a news release. Quell […]
FTC to refund Neurometrix consumers $3.9M in false ad case
The Federal Trade Commission announced that it is refunding NeuroMetrix (NSDQ:NURO) consumers nearly $3.9 million after false advertising. NeuroMetrix marketed its Quell transcutaneous electrical nerve stimulation device as a clinically proven and FDA-cleared treatment for widespread chronic pain relief when placed below the knee, according to the FTC, which said that the company lacks scientific evidence […]
Theranica lands CE mark for migraine device
Theranica announced today that it received CE Mark approval for its Nerivio device for the acute treatment of migraine. Montclair, N.J.-based Theranica adds European approval just over a year since it received FDA de novo clearance for the neurostimulation device in May 2019. The approval allows for the company to begin marketing the device in […]
The 18 most innovative medical devices of 2020
The Galien Foundation recently announced nominees for most innovative medical devices for its 14th Annual Prix Galien USA Awards. The foundation bestows the Prix Galien Award annually to examples of outstanding biomedical and technology products that are designed to improve the human condition. “As we celebrate 50 years of the Prix Galien process, we are honored […]
People can now control their Abbott neuromod device over their iPhone
Abbott (NYSE:ABT) announced today that it received FDA approval for the use of its Patient Controller app on compatible Apple smartphone devices. The company’s Patient Controller app offers management tools for patients with implanted neuromodulation devices to treat conditions such as chronic pain or movement disorders. Now, with the latest approval from the FDA, it’s possible […]
NeuroMetrix improves bottom line despite nearly halved Q2 sales
NeuroMetrix (NSDQ:NURO) shares dipped today after posting second-quarter results that reflected the effects of the COVID-19 pandemic. The Woburn, Mass.-based pain-treating transcutaneous electrical nerve stimulation (TENS) device developer posted losses of -$851,944 on sales of $$1.4 million for the three months ended June 30, 2020, for a 74.7% bottom-line gain on a sales decline of 42.2%. […]
FDA approves Mainstay Medical neurostim device
Mainstay Medical announced that it received FDA premarket approval for its ReActiv8 implantable neurostimulation system for chronic low back pain. ReActiv8 treats intractable chronic low back pain associated with multifidus muscle dysfunction, as evidenced by imaging or physiological testing in adults who have failed therapy and are not candidates for spine surgery, according to a […]
